Literature DB >> 22575797

Diabetic retinopathy screening and monitoring of early stage disease in general practice: design and methods.

Deborah A Askew1, Lisa Crossland, Robert S Ware, Stephen Begg, Peter Cranstoun, Paul Mitchell, Claire L Jackson.   

Abstract

Diabetic retinopathy is the leading cause of preventable blindness in Australians younger than 60 years, mainly from the development of diabetic macular oedema and the sequelae of advanced proliferative diabetic retinopathy. However, early detection and subsequent treatment of diabetic retinopathy, as recommended in Australian national guidelines, can prevent nearly all cases of severe vision loss and blindness, but few people achieve this goal. This paper describes the design and methods of an open controlled trial that aims to assess the feasibility, acceptability, and relative costs and benefits of identification and management of early stages of diabetic retinopathy in primary care, with tele-ophthalmic support and education. A mix of urban, regional and rural general practices across Queensland, Australia are participating in this study, with control practices matched to intervention practices by geographic location, size, patient profile, and shared hospital referral pathways. Outcome measures include the quality of the retinal photographs, the general practitioners' diagnostic accuracy, the acceptability of this intervention to patients, general practice staff and ophthalmologists, screening rates, appropriate monitoring of early stage disease, and the cost-effectiveness of this model, compared to usual care. If proven to be effective, this model of diabetic retinopathy screening and early disease stage monitoring has the potential to improve access to appropriate care. The trial is registered with the Australian New Zealand Clinical Trials Registry (ACTRN 00336192).
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22575797     DOI: 10.1016/j.cct.2012.04.011

Source DB:  PubMed          Journal:  Contemp Clin Trials        ISSN: 1551-7144            Impact factor:   2.226


  6 in total

1.  Interoperative fundus image and report sharing in compliance with integrating the healthcare enterprise conformance and web access to digital imaging and communication in medicine persistent object protocol.

Authors:  Hui-Qun Wu; Zheng-Min Lv; Xing-Yun Geng; Kui Jiang; Le-Min Tang; Guo-Min Zhou; Jian-Cheng Dong
Journal:  Int J Ophthalmol       Date:  2013-12-18       Impact factor: 1.779

Review 2.  Cost-effectiveness of Different Diabetic Retinopathy Screening Modalities.

Authors:  Francisco J Pasquel; Andrew M Hendrick; Martha Ryan; Emily Cason; Mohammed K Ali; K M Venkat Narayan
Journal:  J Diabetes Sci Technol       Date:  2015-12-29

3.  Modeling a Telemedicine Screening Program for Diabetic Retinopathy in Iran and Implementing a Pilot Project in Tehran Suburb.

Authors:  Sare Safi; Hamid Ahmadieh; Marzieh Katibeh; Mehdi Yaseri; Homayoun Nikkhah; Saeed Karimi; Ramin Nourinia; Ali Tivay; Mohammad Zareinejad; Mohsen Azarmina; Alireza Ramezani; Siamak Moradian; Mohammad Hossein Dehghan; Narsis Daftarian; Davood Abbasi; Afshin Eshghi Fallah; Bahareh Kheiri
Journal:  J Ophthalmol       Date:  2019-03-04       Impact factor: 1.909

4.  An Innovative Australian Outreach Model of Diabetic Retinopathy Screening in Remote Communities.

Authors:  Nicola M Glasson; Lisa J Crossland; Sarah L Larkins
Journal:  J Diabetes Res       Date:  2015-12-20       Impact factor: 4.011

5.  Diabetic retinopathy risk prediction for fundus examination using sparse learning: a cross-sectional study.

Authors:  Ein Oh; Tae Keun Yoo; Eun-Cheol Park
Journal:  BMC Med Inform Decis Mak       Date:  2013-09-13       Impact factor: 2.796

6.  Diabetic Retinopathy Screening and Monitoring of Early Stage Disease in Australian General Practice: Tackling Preventable Blindness within a Chronic Care Model.

Authors:  Lisa Crossland; Deborah Askew; Robert Ware; Peter Cranstoun; Paul Mitchell; Andrew Bryett; Claire Jackson
Journal:  J Diabetes Res       Date:  2015-12-20       Impact factor: 4.011

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.